Literature DB >> 17588213

Medication use and disease management of type 2 diabetes in Belgium.

Els Mehuys1, Leen De Bolle, Luc Van Bortel, Lieven Annemans, Inge Van Tongelen, Jean-Paul Remon, Mimi Giri.   

Abstract

OBJECTIVE: The aim of this study was (International Diabetes Federation. Diabetes Atlas Second Edition Executive Summary. Brussels: International Diabetes Federation; 2003) to describe the current status of medication use and disease management of type 2 diabetic patients in Flanders (Belgium), (World Health Organization. Prevention of diabetes mellitus. Technical report series no. 844. Geneva: World Health Organization; 1994) to identify the aspects of type 2 diabetes care a community pharmacist could provide additional educational services for, and (American Diabetes Association. Diabetes Care 2006;29:S4-42) to propose these services as a pharmacist intervention.
METHOD: We recruited 338 patients in 77 community pharmacies in Flanders (Belgium). Each patient completed a questionnaire collecting personal data, information on duration of diabetes, medication, diabetes symptoms and self-management. At inclusion, patients measured their fasting plasma glucose (FPG) on three consecutive days. Prescription drugs (antidiabetic and other) purchased by each patient during the 12 months prior to inclusion in the study were reviewed from anonymized computerized pharmacy records. MAIN OUTCOME MEASURES: Degree of self-management, glycaemic control and medication use.
RESULTS: The mean FPG of the sample was 150.7+/-43.0 mg/dl. Controlled glycaemia (FPG between 90 and 130 mg/dl (5.0-7.2 mmol/l)) was achieved in only 34.9% of the patients. Mainstay of hypoglycemic treatment consisted of metformin monotherapy (29.6%) and metformin combined with sulfonylurea (29.0%). Regarding co-medication, 76.9% of the patients used antihypertensive drugs whereas only 33.1% and 39.9% were on aspirin and statin therapy, respectively. ADA recommendations for annual eye and foot examination were not followed in 38.8% (eye) and 39.2% (feet) of the patients.
CONCLUSION: The current management of type 2 diabetic Flemish patients falls short of recommended treatment goals. Community pharmacists may play a role in enhancing the awareness of glycaemic control and in stimulating self-management in diabetic patients by motivating patients towards correct medication use, better medication adherence, healthy lifestyle and smoking cessation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17588213     DOI: 10.1007/s11096-007-9140-0

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  22 in total

1.  Improving outcomes of community-dwelling older patients with diabetes through pharmacist counseling.

Authors:  R W Baran; K Crumlish; H Patterson; J Shaw; W G Erwin; J D Wylie; P Duong
Journal:  Am J Health Syst Pharm       Date:  1999-08-01       Impact factor: 2.637

2.  Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control.

Authors:  Susan L Norris; Joseph Lau; S Jay Smith; Christopher H Schmid; Michael M Engelgau
Journal:  Diabetes Care       Date:  2002-07       Impact factor: 19.112

3.  Standards of medical care in diabetes--2006.

Authors: 
Journal:  Diabetes Care       Date:  2006-01       Impact factor: 19.112

4.  Opportunities and responsibilities in pharmaceutical care.

Authors:  C D Hepler; L M Strand
Journal:  Am J Hosp Pharm       Date:  1990-03

5.  The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program.

Authors:  Carole W Cranor; Barry A Bunting; Dale B Christensen
Journal:  J Am Pharm Assoc (Wash)       Date:  2003 Mar-Apr

Review 6.  Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin.

Authors:  L M C Welschen; E Bloemendal; G Nijpels; J M Dekker; R J Heine; W A B Stalman; L M Bouter
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 7.  Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials.

Authors:  S L Norris; M M Engelgau; K M Narayan
Journal:  Diabetes Care       Date:  2001-03       Impact factor: 19.112

8.  Evaluation of risk factors for development of complications in Type II diabetes in Europe.

Authors:  A Liebl; M Mata; E Eschwège
Journal:  Diabetologia       Date:  2002-06-19       Impact factor: 10.122

9.  Implementation and evaluation of Australian pharmacists' diabetes care services.

Authors:  Carol L Armour; Susan J Taylor; Fleur Hourihan; Carlene Smith; Ines Krass
Journal:  J Am Pharm Assoc (2003)       Date:  2004 Jul-Aug

10.  Management of patients with type 2 diabetes by pharmacists in primary care clinics.

Authors:  E A Coast-Senior; B A Kroner; C L Kelley; L E Trilli
Journal:  Ann Pharmacother       Date:  1998-06       Impact factor: 3.154

View more
  5 in total

1.  Impact of reimbursement changes on statin use among patients with diabetes in Austria.

Authors:  Wolfgang C Winkelmayer; Markus Asslaber; Anna Bucsics; Thomas Burkhardt; Alexandra Schautzer; Peter Wieninger; Michaela Pogantsch; M Alan Brookhart
Journal:  Wien Klin Wochenschr       Date:  2010-02       Impact factor: 1.704

Review 2.  Systematic review of community pharmacy-based and pharmacist-led foot care interventions for adults with type 2 diabetes.

Authors:  Allison L Soprovich; Vishal Sharma; Lisa Tjosvold; Dean T Eurich; Jeffrey A Johnson
Journal:  Can Pharm J (Ott)       Date:  2019-02-15

Review 3.  The relationship between mean platelet volume and diabetic retinopathy: a systematic review and meta-analysis.

Authors:  ShuaiFei Ji; Jie Zhang; XiuDe Fan; XiQiang Wang; XiaoNa Ning; BaBo Zhang; Heng Shi; Hong Yan
Journal:  Diabetol Metab Syndr       Date:  2019-03-12       Impact factor: 3.320

4.  Increasing trends of diabetes mellitus and body weight: a ten year observation at gondar university teaching referral hospital, northwest ethiopia.

Authors:  Solomon Mekonnen Abebe; Yemane Berhane; Alemayehu Worku; Shitay Alemu
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

5.  Correlation between RAGE gene promoter methylation and diabetic retinal inflammation.

Authors:  Shifeng Kan; Jing Wu; Chengxi Sun; Jing Hao; Zhen Wu
Journal:  Exp Ther Med       Date:  2017-10-26       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.